Clinical Study to evaluate Somatostatin and Some Hormones Levels in Women with Polycystic Ovary Syndrome

Background: Polycystic ovary syndrome (PCOS) is an ovarian disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. It may be the most common female endocrinopathy in the developed world, Its associated with increase insulin secretion (hyperinsulinaemia) and metabolic disease. PCOS is a prevalent and complicated endocrine disease of females. Objective : This study aim to investigate the relationship between somatostatin hormone and its receptor and evaluation of total testosterone, Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH) levels and prolactin in polycystic ovarian syndrome (PCOS). Materials and methods: The study involved 90 patient females, the age ranged between 15 to 40 years old, which were divided into three groups. The first group is comprised 30 obese women, the second is comprised 30 non-obese women who have PCOS and the third group is the control group, which is comprised of 30 women who look to be in good health. The blood concentrations of somatostatin and somatostatin receptor-2 were measured using an enzyme-linked immunosorbent assay. The Cobas e411 analyzer was used to measure the total testosterone, Luteinizing Hormone, Follicle-Stimulating Hormone and prolactin. Results: The results of the current study showed that there was no significant difference in the levels of Somatostatin and Somatostatin receptor2 between obese and non-obese woman groups at p value > 0.05, but there was a significant difference in Somatostatin, Somatostatin receptor-2, and total testosterone, Luteinizing Hormone, Follicle-Stimulating Hormone levels in the obese and non-obese woman groups when compared to controls at p value (p˂0.05). Conclusion: According to the study, there is a positive correlation between Somatostatin and Somatostatin receptor2 in women with PCOS. Additionally, blood levels of total testosterone Luteinizing Hormone, were considerably higher but levels of Follicle-Stimulating Hormone were lower in women with polycystic ovarian syndrome.